Physician profile
Lori Arbital
NPI 1366433807
$2,605.52
in general payments reported to CMS, 2019-2025
19 companies · $759 in 2025
The $759 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $323 · 2021: $133 · 2022: $131 · 2023: $161 · 2024: $784 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $508.68 | 2019-2025 | Precision 1, Precision7, Eysuvis |
| Bausch & Lomb Americas INC. | $352.11 | 2023-2025 | Miebo, Vyzulta, Infuse |
| Sun Pharmaceutical Industries INC. | $250.00 | 2024-2025 | |
| Amgen INC. | $205.80 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $190.90 | 2020-2023 | |
| Harrow Eye, LLC | $166.58 | 2024-2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $124.99 | 2025 | Acuvue |
| Dompe US, INC. | $122.19 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $118.59 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $106.87 | 2024 | |
| Visioneering Technologies, INC. | $96.11 | 2019 | |
| Aerie Pharmaceuticals, INC. | $73.32 | 2019 | |
| Sight Sciences, INC. | $72.47 | 2019 | |
| Genzyme Corporation | $55.85 | 2020 | |
| Coopervision INC. | $52.81 | 2019-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $45.66 | 2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $23.99 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.36 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Arbital listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.